A systematic review and meta-analysis to assess the recurrence-free survival in nonmuscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral resection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. We conducted a meta-analysis assessing the effect of photodynamic diagnosis (PDD) -guided transurethral resection of the bladder tumor (TURB) on the recurrence-free survival in patients with non-muscle invasive bladder cancer within prospective randomised trials that used 5-aminolevulinic acid as a photosensitizer. Matherial and methods. Medical literature search was performed up to February 2016. Recurrence hazard ratios (HRs) and its 95% confidence intervals (CI) were calculated for each selected study with direct and indirect methods and the pooled estimates were obtained with randomeffects model. Results. Data from 5 prospective randomized trials with inclusion of 1089 patients were selected. Pooled estimate of recurrence HR was 0.71 (95% CI 0.48-1.04, p=0.08) with significant heterogeneity across selected publications: p=0,001; 1=78%. The subgroup analysis substantially reduced the heterogeneity: in subgroup comprising single/two-center studies or with moderate to high risk of bias or with long follow-up there was significant benefit of PDD-assisted TURBT (HR 0.51, 95% CI 0.38-0.69;p<0.0001), while in multicenter studies or those with low risk of bias or short follow-up the effect size was within the statistical error limits (HR 1.04, 95% CI 0.77-1.42, p=0.78). Conclusions. Statistically significant benefit of PDD-guided TURBT over the white-light TURBT was limited to single/two-center studies or with moderate to high risk of bias or with long follow-up. True meaning of these finding it is not clear due to possibility of alternative explanations of identified differences. Generally there was low quality of evidence from significant proportion of studies and risk of publication bias.

Full Text

Restricted Access

About the authors

A. I Rolevich

N.N. Alexandrov National Cancer Centre

Email: alexander.rolevich@gmail.com
Division of Oncourology, Department of Surgery

A. A Evmenenko

N.N. Alexandrov National Cancer Centre

Email: evmenenkoalesya88@gmail.com
Department of Cancer Control

References

  1. Ferlay J., Soerjomataram I.,. Ervik M. et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 6/01/2016.
  2. Botteman M.F., Pashos C.L., Redaelli A. et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315-1330.
  3. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol. 1999;162(1):74-76.
  4. Brausi M., Collette L., Kurth K. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523-531.
  5. Kriegmair M., Baumgartner R., Knuechel R. et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994;44(6):836-841.
  6. Burger M., Stief C.G., Zaak D. et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology. 2009;74(6):1282-1286.
  7. Rink M., Babjuk M., Catto J.W. et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624-638.
  8. Lotan Y. Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: con. J. Urol. 2012;187(5):1538-539.
  9. Shen P., Yang J., Wei W. et al. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU Int. 2012;110(6 Pt B):E209-215.
  10. Yuan H., Qiu J., Liu L. et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(9):e74142.
  11. Higgins J.P., Altman D.G., G0tzsche P.C. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ. 2011 18;343:d5928.
  12. Deeks J.J., Higgins J.P.T., Altman D.G. (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. [Electronic resource] Available from www.cochrane-handbook.org.
  13. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834.
  14. Williamson P.R., Smith C.T., Hutton J.L., Marson A.G. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337- 3351.
  15. Tierney J.F., Stewart L.A., Ghersi D. et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7;8:16.
  16. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
  17. Babjuk M., Soukup V., Petn'k R. et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96(6):798-802.
  18. Daniltchenko D.I., Riedl C.R., Sachs M.D. et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J. Urol. 2005;174(6):2129-2133.
  19. Filbeck T., Pichlmeier U., Knuechel R. et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J. Urol. 2002;168(1):67-71.
  20. Riedl C.R., Daniltchenko D., Koenig F., et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J. Urol. 2001;165(4):1121-1123.
  21. Denzinger S., Burger M., Walter B. et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007;69(4):675-679.
  22. Denzinger S., Wieland W.F., Otto W. et al. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int. 2008;101(5):566-569.
  23. Alken P., Siegsmund M., Gromoll-Bergmann K. et al. A randomized controlled multicentre trial to compare the effects of transurethral resection of bladder carcinomas under 5-ALA induced fluorescence light to conventional white light. In: Proceedings from the Annual Congress of the European Association of Urology; March 21-24, 2007; Berlin, Germany. Abstract 593.
  24. Schumacher M.C., Holmäng S., Davidsson T. et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol. 2010;57(2):293- 299.
  25. Stenzl A., Penkoff H., Dajc-Sommerer E. et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: A multicenter randomized, double-blind, placebo-controlled trial. Cancer. 2011;117(5):938-947.
  26. Kausch I., Sommerauer M., Montorsi F. et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57(4):595-606.
  27. Mowatt G., Zhu S., Kilonzo M. et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14(4):1-331, iii-iv.
  28. Mowatt G., N’Dow J., Vale L. et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J. Technol Assess Health Care. 2011;27(1):3-10.
  29. Burger M., Grossman H.B., Droller M. et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846-854.
  30. Lee J.Y., Cho K.S., Kang D.H. et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015;15:566.
  31. Babjuk M., Gontero P., Jacqmin D. et al. (2014, may, 09) Re: Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Letter to the Editor. [Electronic resource] http://www.bjuinternational.com/letters/ re-effects-of-fluorescent-light-guided-transurethral-resection-on-nmibc/
  32. Kriegmair M., Zaak D., Rothenberger K.H. et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J. Urol. 2002;168(2):475-478.
  33. Herr H.W., Donat S.M. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9 Pt B):1242-1246.
  34. Vickers A., Savage C., Bianco F. et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol. 2011;59(3):317-322.
  35. Trinh Q.D., Bjartell A., Freedland S.J. et al. A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol. 2013;64(5):786-798.
  36. Hu J.C., Yu H.Y., Kowalczyk K.J. Challenges of interpreting and improving radical prostatectomy outcomes: technique, technology, training, and tactical reporting. Eur Urol. 2011;59(6):1073-1074.
  37. Draga R.O., Grimbergen M.C., Kok E.T. et al. The quality of 5-aminolevulinic acid-induced photodynamic diagnosis and transurethral resection of bladder tumors: does the urologist play a role? UrolInt. 2012;89(3):326-331.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies